A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1813-1820

  Seiwert, T Y ^a   Fayette, J ^b   Cupissol, D ^c   del Campo, J M ^d   Clement, P M ^e   Hitt, R ^f   Degardin, M ^g   Zhang, W ^h   Blackman, A ⁱ   Ehrnrooth, E ^j   Cohen, E E W ^k  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE VAL D AURELLE   (France)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^g CENTRE OSCAR LAMBRET   (France)

^h Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd   (China)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Afatinib; Cetuximab; EGFR inhibitor therapy; Metastatic HNSCC; Recurrent HNSCC

Indexed keywords

AFATINIB; CETUXIMAB; VASCULOTROPIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN P16; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EYE DISEASE; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAIL DISEASE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; SURVIVAL RATE; TUMOR VOLUME; VOMITING; AGED; BELGIUM; CONJUNCTIVITIS; CROSS RESISTANCE; DISEASE CONTROL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TOLERABILITY; EGFRVIII GENE; FRANCE; GENE; GENE MUTATION; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; OPEN STUDY; P16 GENE; PARONYCHIA; PERIORBITAL EDEMA; SPAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; HEAD AND NECK NEOPLASMS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903764970     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu216     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F et al. 2008 GLOBOCAN 2008: Cancer incidence and mortality worldwide: IARC cancerbase no. 10; http://globocan.iarc.fr (31 March 2014, date last accessed).
2. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4: 156-171.
3. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115: 922-935.
4. Hayes DN, Grandis J, El-Naggar AK. Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas. In Presented at the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 6-10 April 2013.
5. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
6. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
7. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
8. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-5073.
9. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702-4711.
10. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342-350.
11. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334.
12. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3342-3350.
13. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
14. Perez CA, Song H, Raez LE et al. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2012; 48: 887-892.
15. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
16. Stewart JS, Cohen EE, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009; 27: 1864-1871.
17. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
18. Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999; 17: 1008-1019.
19. Jeuken J, Sijben A, Alenda C et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 2009; 19: 661-671.
20. Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 1981; 4: 451-457.
21. Karrison TG, Maitland ML, Stadler WM et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007; 99: 1455-1461.
22. Stransky N, EgloffAM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
23. Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011; 18: 126-138.
24. Yang JC, Reguart N, BarinoffJ et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013; 13: 729-736.